PMID- 23146450
OWN - NLM
STAT- MEDLINE
DCOM- 20130613
LR  - 20181202
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 9
DP  - 2012 Nov
TI  - Monitoring of circulating antibodies in a renal transplantation population: 
      preliminary results.
PG  - 2548-50
LID - S0041-1345(12)01054-8 [pii]
LID - 10.1016/j.transproceed.2012.09.072 [doi]
AB  - BACKGROUND: The presence of circulating antibodies (CA) against human leukocyte 
      antigen (HLA) and major-histocompatibility-complex class I-related chain A (MICA) 
      antigens has been associated with worse renal function and reduced kidney 
      allograft survival. We sought to describe the presence of donor-specific anti-HLA 
      antibodies, non-donor specific antibodies, and antibodies against MICA antigens 
      among a cohort of renal transplant recipients with respect to their evolution 
      effects on renal function and occurrence of an acute rejection episode (AR) after 
      transplantation. METHODS: This prospective study of 22 renal transplant 
      recipients of deceased donor kidneys underwent studies of antibodies before and 3 
      months after grafting using Luminex technology. RESULTS: Ten patients (five men 
      and five women) showed preexistent CA. Comparing patients with versus without 
      preformed CA, we did not observe a significant difference in donor and recipient 
      age or gender. Eight patients (80%) with CA had undergone induction treatment 
      with anti-human-activated T-lymphocyte rabbit immunoglobulin and 2 (20%) with 
      basiliximab. There were no differences between groups regarding the incidence of 
      acute rejection episodes (ARE n = 3 each). There was one case of Banff grade IIB 
      ARE in a patient without preexisting CA; the other episodes were low-grade 
      cellular responses. There were no differences in other variables including cold 
      ischemia time, HLA mismatches, panel-reactive antibody levels, number of 
      transfusions, cytomegalovirus infection or renal function at discharge and 3 
      months later. Retransplantation was the only factor associated with preformed CA. 
      Retransplantation and preformed CA were associated with CA at 3 months after 
      transplantation. CONCLUSIONS: CA monitoring is important for highly sensitized 
      renal transplants, although our experience failed to show a difference in graft 
      survival or renal function in the first 3 months' follow-up.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Rodriguez Ferrero, M L
AU  - Rodriguez Ferrero ML
AD  - Nephrology Department, Hospital General Universitario Gregorio Maranon, Madrid, 
      Spain. mlrodriguezf@senefro.org
FAU - Arroyo, D
AU  - Arroyo D
FAU - Panizo, N
AU  - Panizo N
FAU - Vicario, J L
AU  - Vicario JL
FAU - Balas, A
AU  - Balas A
FAU - Anaya, F
AU  - Anaya F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantibodies)
RN  - 0 (MHC class I-related chain A)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9927MT646M (Basiliximab)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antilymphocyte Serum/therapeutic use
MH  - Basiliximab
MH  - Biomarkers/blood
MH  - Female
MH  - Graft Rejection/epidemiology/immunology/surgery
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Incidence
MH  - Isoantibodies/*blood
MH  - Kidney Transplantation/adverse effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Immunologic
MH  - Prospective Studies
MH  - Recombinant Fusion Proteins/therapeutic use
MH  - Reoperation
MH  - Risk Factors
MH  - Spain/epidemiology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/11/14 06:00
MHDA- 2013/06/14 06:00
CRDT- 2012/11/14 06:00
PHST- 2012/11/14 06:00 [entrez]
PHST- 2012/11/14 06:00 [pubmed]
PHST- 2013/06/14 06:00 [medline]
AID - S0041-1345(12)01054-8 [pii]
AID - 10.1016/j.transproceed.2012.09.072 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Nov;44(9):2548-50. doi: 10.1016/j.transproceed.2012.09.072.